$0.12
(Market cap
$3 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-12.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
-2.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
286,504
10 Years Aggregate
CFO
€-112.54 Mln
EBITDA
€-130.13 Mln
Net Profit
€-149.81 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biophytis (BPTS)
| 947.7 | -7.7 | 1,750.0 | 197.9 | -60.1 | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Biophytis (BPTS)
| -83.0 | -92.6 |
|
BSE Sensex
| 18.7 | 4.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biophytis (BPTS)
|
7.0 | 2.6 | 0.0 | -17.0 | -- | 591.2 | -- | 2.3 |
| 1,028.3 | 64,558.4 | 8,446.3 | 2,595.8 | 21.8 | 33 | 39.5 | 7.7 | |
| 13.7 | 914.4 | 0.0 | -175.9 | -- | -106.8 | -- | 5.6 | |
| 23.0 | 12,469.9 | 19,427.2 | 937.8 | 9.6 | 5.1 | 12.4 | 0.9 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 2.2 | 252.4 | 2.8 | -49.2 | -86.4 | 764.8 | -- | 20.1 | |
| 4.7 | 1,105.5 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 41.3 | 2,212.5 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 | |
| 6.4 | 660.0 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.9 |
Shareholding Pattern
View DetailsAbout Biophytis (BPTS)
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on... targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France. Read more
-
Chairman of the Board & CEO
Mr. Stanislas Veillet Ph.D.
-
Chairman of the Board & CEO
Mr. Stanislas Veillet Ph.D.
-
Headquarters
Paris
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biophytis (BPTS)
What is the current share price of Biophytis (BPTS) Today?
The share price of Biophytis (BPTS) is $7.03 (NASDAQ) as of 27-Jun-2024 09:30 EDT. Biophytis (BPTS) has given a return of -60.06% in the last 3 years.
What is the current PB & PE ratio of Biophytis (BPTS)?
Since, TTM earnings of Biophytis (BPTS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Biophytis (BPTS)?
The 52-week high and low of Biophytis (BPTS) are Rs -- and Rs -- as of 29-Aug-2026.
What is the market cap of Biophytis (BPTS)?
Biophytis (BPTS) has a market capitalisation of $ 3 Mln as on 27-Jun-2024. As per SEBI classification, it is a company.
Should I invest in Biophytis (BPTS)?
Before investing in Biophytis (BPTS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.